Evidence map›Paper›PMID 38042958›Full record

ArticleBritish journal of cancer2024

Stromal localization of inactive CD8

Emre Küçükköse, Matthijs J D Baars, Mojtaba Amini, Suzanna J Schraa, Evelien Floor, Guus M Bol, Inne H M Borel Rinkes, Jeanine M L Roodhart, Miriam Koopman, Jamila Laoukili and 2 more

Open access · greenAbstract read
In one paragraph

Article in British journal of cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Unraveling the Effects and Characteristics of Proliferating Tumor and Cytotoxic T Cells in Colorectal Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Cold and hot tumors: from molecular mechanisms to targeted therapy.Signal transduction and targeted therapy · 2024
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Emre Küçükköse *Division of Imaging and Cancer, Laboratory Translational Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID 0000-0002-8983-9464
Matthijs J D Baars *Center for Molecular Medicine, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.ORCID 0000-0003-4741-051X
Mojtaba AminiCenter for Molecular Medicine, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.ORCID 0009-0009-8301-0178
Suzanna J SchraaDivision of Imaging and Cancer, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Evelien FloorCenter for Molecular Medicine, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.ORCID 0000-0002-1170-5044
Guus M BolDivision of Imaging and Cancer, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Inne H M Borel RinkesDivision of Imaging and Cancer, Laboratory Translational Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Jeanine M L RoodhartDivision of Imaging and Cancer, Laboratory Translational Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID 0000-0003-1398-8970
Miriam KoopmanDivision of Imaging and Cancer, Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.ORCID 0000-0003-1550-1978
Jamila LaoukiliDivision of Imaging and Cancer, Laboratory Translational Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
Onno Kranenburg *Division of Imaging and Cancer, Laboratory Translational Oncology, University Medical Center Utrecht, Utrecht, The Netherlands. o.kranenburg@umcutrecht.nl.ORCID 0000-0002-2112-4390
Yvonne Vercoulen *Center for Molecular Medicine, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands. y.vercoulen@umcutrecht.nl.ORCID 0000-0002-5060-2603
Utrecht University · NLUniversity Medical Center Utrecht · NL

Funding

KWF Kankerbestrijding (Dutch Cancer Society) UU-10660
6 · The paper itself

Abstract

backgroundThe determinants of metastasis in mismatch repair deficiency with high levels of microsatellite instability (MSI-H) in colorectal cancer (CRC) are poorly understood. Here, we hypothesized that distinct immune and stromal microenvironments in primary tumors may discriminate between non-metastatic MSI-H CRC and metastatic MSI-H CRC.

methodsWe profiled 46,727 single cells using high-plex imaging mass cytometry and analyzed both differential cell type abundance, and spatial distribution of fibroblasts and immune cells in primary CRC tumors with or without metastatic capacity. We validated our findings in a second independent cohort using immunohistochemistry.

resultsHigh-plex imaging mass cytometry and hierarchical clustering based on microenvironmental markers separated primary MSI-H CRC tumors with and without metastatic capacity. Primary tumors with metastatic capacity displayed a high stromal content and low influx of CD8

conclusionWe conclude that localization of phenotypically distinct CD8

Indexed as

Colonic NeoplasmsColorectal NeoplasmsRectal NeoplasmsCD8-Positive T-LymphocytesDNA Mismatch RepairHumansMicrosatellite InstabilityPrognosisTumor Microenvironment

Identifiers

PMID38042958
PMCPMC10803761
OpenAlexW4389264713

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.